A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines

There are no files associated with this record.

Title A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines
Author Middelberga, Anton P.J.; Rivera-Hernandeza, Tania; Wibowoa, Nani; Luaa, Linda H.L.; Fana, Yuanyuan; Magor, Graham; Changa, Cindy; Chuana, Yap P.; Good, Michael Francis; Batzloff, Michael Raymond
Journal Name Vaccine
Year Published 2011
Place of publication United Kingdom
Publisher Elsevier Ltd
Abstract Studies on a platform technology able to deliver low-cost viral capsomeres and virus-like particles are described. The technology involves expression of the VP1 structural protein from murine polyomavirus (MuPyV) in Escherichia coli, followed by purification using scaleable units and optional cell-free VLP assembly. Two insertion sites on the surface of MuPyV VP1 are exploited for the presentation of the M2e antigen from influenza and the J8 peptide from Group A Streptococcus (GAS). Results from testing on mice following subcutaneous administration demonstrate that VLPs are self adjuvating, that adding adjuvant to VLPs provides no significant benefit in terms of antibody titre, and that adjuvanted capsomeres induce an antibody titre comparable to VLPs but superior to unadjuvanted capsomere formulations. Antibodies raised against GAS J8 peptide following immunization with chimeric J8-VP1 VLPs are bactericidal against a GAS reference strain. E. coli is easily and widely cultivated, and well understood, and delivers unparalleled volumetric productivity in industrial bioreactors. Indeed, recent results demonstrate that MuPyV VP1 can be produced in bioreactors at multi-gram-per-litre levels. The platform technology described here therefore has the potential to deliver safe and efficacious vaccine, quickly and cost effectively, at distributed manufacturing sites including those in less developed countries. Additionally, the unique advantages of VLPs including their stability on freeze drying, and the potential for intradermal and intranasal administration, suggest this technology may be suited to numerous diseases where adequate response requires large-scale and low-cost vaccine manufacture, in a way that is rapidly adaptable to temporal or geographical variation in pathogen molecular composition.
Peer Reviewed Yes
Published Yes
Alternative URI http://dx.doi.org/10.1016/j.vaccine.2011.05.075
Volume 29
Issue Number 41
Page from 7154
Page to 7162
ISSN 1873-2518
Date Accessioned 2012-03-06; 2012-03-21T23:15:02Z
Date Available 2012-03-21T23:15:02Z
Research Centre Institute for Glycomics
Faculty Faculty of Science, Environment, Engineering and Technology
Subject Infectious Agents
URI http://hdl.handle.net/10072/43770
Publication Type Journal Articles (Refereed Article)
Publication Type Code c1

Show simple item record

Griffith University copyright notice